EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy

Rees, Margaret; Pérez‐López, Faustino R.; Ceasu, Iuliana; Depypere, Herman; Erel, C. Tamer; Lambrinoudaki, Ιrene; Schenck‐Gustafsson, Karin; Simoncini, Tommaso; Schouw, Yvonne T. van der; Trémollières, Florence

doi:10.1016/j.maturitas.2012.06.009

Cited by 65 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Absorption depends on the dose used and the degree of vaginal atrophy. Thus plasma estrogen levels do not exceed the normal postmenopausal range of ≤ 20 pg/ml with long term use of 10mcg estradiol tablets and does not increase the risk of endometrial hyperplasia and carcinoma [5,21,24]. On the other hand, absorption may be higher when treatment is initiated as the vaginal epithelium is thin and atrophic.…”

Section: Topical and Systemic Hormone Therapymentioning

confidence: 98%

“…For example urinary urgency can result from overactive bladder, whose etiology is often multifactorial and where antimuscarinic drugs are the most common treatment [2]. On the other hand, estrogens are useful in the prevention of recurrent urinary tract infections and vaginal dryness [3][4][5][6][7].…”

Section: What Is Genitourinary Syndrome Of Menopause?mentioning

confidence: 99%

“…Given their proven efficacy and safety, this section will focus on topical estrogens [21]. A Cochrane review examined the literature on topical estrogens in 2006 [22] and the European Menopause and Andropause Society published a clinical guide in 2012 on the low dose preparations which had since become available [5]. The literature supports the efficacy of lower doses to minimize adverse effects [23].…”

Section: Topical and Systemic Hormone Therapymentioning

confidence: 99%

“…However GSM is a chronic condition and will recur upon cessation of treatment. It is probably prudent to review women's needs annually to assess efficacy and acceptability while updating on any new advice, information or treatment options [5].…”

Section: Follow-upmentioning

confidence: 99%

See 3 more Smart Citations

Update on management of genitourinary syndrome of menopause: A practical guide

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Topical and Systemic Hormone Therapymentioning

confidence: 98%

Section: What Is Genitourinary Syndrome Of Menopause?mentioning

confidence: 99%

Section: Topical and Systemic Hormone Therapymentioning

confidence: 99%

Section: Follow-upmentioning

confidence: 99%

See 2 more Smart Citations

Update on management of genitourinary syndrome of menopause: A practical guide

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…This can occur naturally or be induced secondary to the follicular depletion by bilateral oophorectomy, radiation to the ovaries, or by chemotherapy effects on ovarian follicular reserves [1] and the vaginal atrophy is common in postmenopausal women 1 Sodium hyaluronate vaginal gel: Lubrinat®. and negatively affects the quality of life [2].…”

Section: Introductionmentioning

confidence: 99%

Perceived Efficacy of Vaginal Dryness Relief: A Comparative Clinical Study between Sodium hyaluronate vaginal gel1 vs. Promestriene cream2

Duque-Estrada¹,

Rosa²,

Mosca³

et al. 2017

ASM

View full text Add to dashboard Cite

In the study, we report the comparative efficacy of the sodium hyaluronate gel vaginal application and promestriene cream which were tested to treat the gynecological symptoms of people who suffered from vaginal dryness. Method: 35 patients applied sodium hyaluronate vaginal gel one time a day for a period of two times a week during three weeks and other 33 patients using promestriene cream applied it every day for a period of three weeks also. Results: No significant difference was observed between vaginal application of sodium hyaluronate gel and promestriene cream, regarding both, as regarding the dryness of the intimate mucosa (p = 0.786), the attribute of moisturizing properties to the intimate mucosa (p = 0.142), the comfort sensation (p = 0.528), and no significant difference was observed regarding the fragrance of the product (p = 0.088). Conclusion: The similar results between vaginal application of both products support the use of sodium hyaluronate vaginal gel (Lubrinat®) in the initial approach of symptoms of vaginal dryness.

show abstract

Vaginal Stricture After Pelvic Organ Prolapse Surgery

Roth

Meeks

Davila

2016

Gynecologic and Obstetric Surgery

View full text Add to dashboard Cite

EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy

Cited by 65 publications

References 29 publications

Update on management of genitourinary syndrome of menopause: A practical guide

Update on management of genitourinary syndrome of menopause: A practical guide

Perceived Efficacy of Vaginal Dryness Relief: A Comparative Clinical Study between <i>Sodium hyaluronate vaginal gel</i><sup>1</sup> <i>vs. Promestriene cream</i><sup>2</sup>

Vaginal Stricture After Pelvic Organ Prolapse Surgery

Contact Info

Product

Resources

About

EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy

Cited by 65 publications

References 29 publications

Update on management of genitourinary syndrome of menopause: A practical guide

Update on management of genitourinary syndrome of menopause: A practical guide

Perceived Efficacy of Vaginal Dryness Relief: A Comparative Clinical Study between &lt;i&gt;Sodium hyaluronate vaginal gel&lt;/i&gt;&lt;sup&gt;1&lt;/sup&gt; &lt;i&gt;vs. Promestriene cream&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;

Vaginal Stricture After Pelvic Organ Prolapse Surgery

Contact Info

Product

Resources

About

Perceived Efficacy of Vaginal Dryness Relief: A Comparative Clinical Study between <i>Sodium hyaluronate vaginal gel</i><sup>1</sup> <i>vs. Promestriene cream</i><sup>2</sup>